| scholarly article | Q13442814 |
| P50 | author | Michael Weller | Q2779469 |
| Guido Reifenberger | Q30004009 | ||
| P2093 | author name string | Christiane Knobbe-Thomsen | |
| Christine K Cheng | |||
| Elizabeth Charron | |||
| Jasmine Lau | |||
| Justin Chen | |||
| Kevan M Shokat | |||
| Natalia Jura | |||
| Petra Zipper | |||
| Qi-Wen Fan | |||
| Robyn A Wong | |||
| W Clay Gustafson | |||
| William A Weiss | |||
| P2860 | cites work | Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3 | Q39560754 |
| Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. | Q40327533 | ||
| RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. | Q40484644 | ||
| The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. | Q40541045 | ||
| Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR | Q40619097 | ||
| Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor | Q42799161 | ||
| STAT3 tyrosine phosphorylation influences survival in glioblastoma | Q43068296 | ||
| Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network | Q43266785 | ||
| Effects of transient changes in silage dry matter concentration on lactating dairy cows | Q43542897 | ||
| Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas | Q47357523 | ||
| Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma | Q49068065 | ||
| Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. | Q55471514 | ||
| The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization | Q62746688 | ||
| Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment | Q24309071 | ||
| Structure-guided development of affinity probes for tyrosine kinases using chemical genetics | Q27643967 | ||
| Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins | Q27860890 | ||
| A chemical switch for inhibitor-sensitive alleles of any protein kinase | Q29614785 | ||
| Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma | Q33370229 | ||
| Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes | Q33669979 | ||
| Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas | Q33881165 | ||
| Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma | Q34069375 | ||
| Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 | ||
| Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma | Q36179166 | ||
| Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation | Q36288511 | ||
| Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. | Q36631618 | ||
| Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252 | Q36785831 | ||
| Structural alterations of the epidermal growth factor receptor gene in human gliomas | Q36930689 | ||
| A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma | Q37003323 | ||
| The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. | Q37020840 | ||
| The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling | Q38349130 | ||
| Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail | Q38609896 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| phosphorylation | Q242736 | ||
| glioblastoma | Q282142 | ||
| epidermal growth factor receptor | Q424401 | ||
| identical protein binding | Q14762994 | ||
| P304 | page(s) | 438-49 | |
| P577 | publication date | 2013-10-14 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma | |
| P478 | volume | 24 |
| Q46093038 | A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. |
| Q37317390 | A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases |
| Q91710831 | A compact synthetic pathway rewires cancer signaling to therapeutic effector release |
| Q55457034 | A glial blueprint for gliomagenesis. |
| Q89823519 | Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
| Q38364234 | Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? |
| Q92856714 | An Insight Into the Molecular Mechanism of Berberine Towards Multiple Cancer Types Through Systems Pharmacology |
| Q31104000 | Antibody Therapies in Cancer |
| Q35804765 | Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells |
| Q45036488 | Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy |
| Q40070524 | Biomarkers and therapeutic advances in glioblastoma multiforme |
| Q35834087 | CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. |
| Q60922784 | COPI-Mediated Nuclear Translocation of EGFRvIII Promotes STAT3 Phosphorylation and PKM2 Nuclear Localization |
| Q37362563 | Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. |
| Q26852366 | Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies |
| Q43376098 | Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. |
| Q35534349 | Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status |
| Q37174174 | Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. |
| Q36214610 | Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells |
| Q28087306 | Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma |
| Q50324498 | Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation |
| Q35612289 | Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms |
| Q89705432 | Dual blockade of STAT3 and EGFR, a key to unlock drug resistance in Glioblastoma? |
| Q99209251 | Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs) |
| Q36821054 | Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival |
| Q42371599 | EGF stimulates glioblastoma metastasis by induction of matrix metalloproteinase-9 in an EGFR-dependent mechanism |
| Q28551853 | EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line |
| Q39383476 | EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment |
| Q40089704 | EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. |
| Q90749189 | EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo |
| Q58605925 | EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma |
| Q47111538 | EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer |
| Q48014727 | EGFR heterogeneity and implications for therapeutic intervention in glioblastoma |
| Q57287793 | EGFR promotes glioma progression by regulating xCT and GluN2B-containing NMDA receptor signaling |
| Q34016908 | EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing |
| Q38199643 | EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. |
| Q64120766 | EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma |
| Q89748217 | EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma |
| Q55457200 | EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival. |
| Q38912207 | EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. |
| Q89848700 | EGFRvIII: An Oncogene with Ambiguous Role |
| Q42367951 | EGFRvIII: the promiscuous mutation |
| Q48546244 | EGFRwt/vIII-PKM2-β-catenin cascade affects proliferation and chemo-sensitivity in head and neck squamous cell carcinoma |
| Q98386373 | ERK-mediated negative feedback regulation of oncogenic EGFRvIII in glioblastoma cells |
| Q50100856 | Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies |
| Q34391942 | Epidermal growth factor receptor and variant III targeted immunotherapy. |
| Q28084216 | Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer |
| Q36977684 | Epidermal growth factor receptor targeting and challenges in glioblastoma |
| Q61805774 | Epilepsy Associates with Decreased HIF-1α/STAT5b Signaling in Glioblastoma |
| Q33619401 | Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma |
| Q37732068 | Expression and clinical value of EGFR in human meningiomas |
| Q33643498 | Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. |
| Q37694758 | GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity |
| Q55457220 | GOLPH3 promotes glioma progression via facilitating JAK2-STAT3 pathway activation. |
| Q47706727 | Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. |
| Q57048305 | Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors |
| Q49678076 | Genomic alterations of ERBB receptors in cancer: clinical implications |
| Q40116157 | Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. |
| Q39002694 | Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo |
| Q38795844 | HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies. |
| Q38969869 | Hematogenous dissemination of glioblastoma multiforme. |
| Q27013006 | Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma |
| Q90317829 | Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains |
| Q47343878 | Identification of a novel fusion gene HMGA2-EGFR in glioblastoma. |
| Q52097937 | In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The φ-Index. |
| Q41338250 | Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. |
| Q28546030 | Inference of Low and High-Grade Glioma Gene Regulatory Networks Delineates the Role of Rnd3 in Establishing Multiple Hallmarks of Cancer |
| Q36759183 | InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma |
| Q45074720 | Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. |
| Q34062038 | JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma |
| Q26797495 | Ligand-Independent EGFR Signaling |
| Q90285524 | Lycorine inhibits glioblastoma multiforme growth through EGFR suppression |
| Q28385366 | Mechanisms of action of therapeutic antibodies for cancer |
| Q38194054 | Microenvironmental clues for glioma immunotherapy |
| Q34043232 | Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells |
| Q26830388 | NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age |
| Q48612184 | NF-κB-dependent transcriptional upregulation of cyclin D1 exerts cytoprotection against hypoxic injury upon EGFR activation |
| Q26773754 | Non-canonical signaling mode of the epidermal growth factor receptor family |
| Q43441906 | Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma |
| Q91826369 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy |
| Q30393905 | Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells |
| Q92086465 | Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages |
| Q89995854 | Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples |
| Q64278894 | Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas |
| Q37190200 | Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis |
| Q38873993 | Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles |
| Q41594903 | Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors |
| Q90161291 | Reduced EGFR Level in eIF2α PhosphorylationDeficient Hepatocytes Is Responsible for Susceptibility to Oxidative Stress |
| Q34886810 | Role of glycosyltransferase PomGnT1 in glioblastoma progression |
| Q35919703 | Role of hypoxia-inducible factor-1α and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma |
| Q54256038 | Role of microRNAs Located on Chromosome Arm 10q in Malignant Gliomas |
| Q52676604 | STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. |
| Q92713838 | STAT3 signaling in ovarian cancer: a potential therapeutic target |
| Q26783920 | Single and Multiple Gene Manipulations in Mouse Models of Human Cancer |
| Q47279032 | TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma. |
| Q47828321 | TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3. |
| Q35800124 | Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma |
| Q92861783 | Targeting of early endosomes by autophagy facilitates EGFR recycling and signalling |
| Q38670567 | The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas |
| Q36917721 | The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-) |
| Q37501595 | The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression |
| Q97542845 | The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma |
| Q35341639 | Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma |
| Q55460052 | [Treatment of the glioma microenvironment]. |
Search more.